A device for screening ALK-positive NSCLC patients using the IHC method typically includes ‘VENTANA ALK (D5F3) CDx Assay (VENTANA Medical Systems, Inc., Oro Valley, AZ, USA)’, which is approved by the FDA. Here, ALK is linked to non-small cell lung carcinoma.